Vancouver, British Columbia–(Newsfile Corp. – December 21, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (“ Lobe” or the “Company“) is pleased to announce its patent-pending therapeutic regimen that has been designed for treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder, and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder has been published by the World…
